Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

BACKGROUND: Tumor samples from the phase III IMpower010 study were used to compare two programmed death-ligand 1 (PD-L1) immunohistochemistry assays (VENTANA SP263 and Dako 22C3) for identification of PD-L1 patient subgroups (negative, positive, low, and high expression) and their predictive value f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Caicun, Srivastava, Minu K, Xu, Hao, Felip, Enriqueta, Wakelee, Heather, Altorki, Nasser, Reck, Martin, Liersch, Rüdiger, Kryzhanivska, Anna, Oizumi, Satoshi, Tanaka, Hiroshi, Hamm, John, McCune, Steven L, Bennett, Elizabeth, Gitlitz, Barbara, McNally, Virginia, Ballinger, Marcus, McCleland, Mark, Zou, Wei, Das Thakur, Meghna, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619123/
https://www.ncbi.nlm.nih.gov/pubmed/37903590
http://dx.doi.org/10.1136/jitc-2023-007047

Ejemplares similares

Ejemplares similares